-
Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage…
-
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
•
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into an agreement with US firm Syncromune, an innovative pharma company focused on the development of next-generation tumor immunotherapies via intratumoral delivery. The collaboration aims to advance the development and commercialization of intratumoral immunotherapy based on…
